W
Walter M. Stadler
Researcher at University of Chicago
Publications - 513
Citations - 37554
Walter M. Stadler is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 88, co-authored 494 publications receiving 34323 citations. Previous affiliations of Walter M. Stadler include Cleveland Clinic & Northwestern University.
Papers
More filters
Journal ArticleDOI
858 safety analysis of the advanced renal cell carcinoma sorafenib (arccs) study, an expanded access program
Journal ArticleDOI
Tasquinimod Mechanism of Action Biomarkers: Correlation with PFS and Survival in Men with Metastatic Castrate Resistant Prostate Cancer Treated in a Randomized Phase 2 Trial
Michael A. Carducci,Andrew J. Armstrong,Michael Häggman,Walter M. Stadler,Jeffrey R. Gingrich,Vasily J. Assikis,Göran Forsberg,A. Olsson,Orjan Nordle,Roberto Pili +9 more
TL;DR: Tasquinimod mechanism of action biomarkers : correlation with pfs and survival in men with metastatic castrate resistant prostate cancer treated in a randomized phase 2 trial.
Journal ArticleDOI
Safety and tolerability of AZD2171, a highly potent VEGFR inhibitor, in patients with advanced prostate adenocarcinoma
Charles J. Ryan,Walter M. Stadler,Bruce J. Roth,Thomas A. Puchalski,Maria Koehler,Eric J. Small +5 more
TL;DR: This Phase I multicenter, open-label, dose-escalation trial was to assess the safety and tolerability of AZD2171 in patients with advanced prostate adenocarcinoma and showed broad-spectrum antitumor activity in a range of histologically diverse xenograft models.
Journal ArticleDOI
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL
Natalie Galanina,Sonali M. Smith,Chuanhong Liao,Adam M. Petrich,Bernadette Libao,Ronald B. Gartenhaus,Jason R. Westin,Kenneth S. Cohen,James A. Knost,Walter M. Stadler,Austin Doyle,Theodore Karrison,Leo I. Gordon,Andrew M. Evens +13 more
TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the response of the immune system to transplants.